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Ameri
e conthe purpose of this science advisory is to summarize
the currently available data concerning thiazo-
lidinediones and cardiovascular risk, with a focus on
schemic heart disease (IHD) events, and to provide practical
ecommendations to healthcare workers seeking to minimize
he burden of cardiovascular disease (CVD) and other com-
lications in their patients with type 2 diabetes mellitus. On
ay 21, 2007, the US Food and Drug Administration (FDA)
eleased a safety alert concerning a possible increased risk of
schemic cardiovascular events in patients prescribed the
hiazolidinedione rosiglitazone. This safety alert was
rompted by the results of a large meta-analysis that reported
hat treatment with rosiglitazone resulted in a 43% increase in
isk for myocardial infarction (MI) and a possible increase in
isk for cardiovascular death (1). These data were particularly
larming because the metabolic effects of thiazolidinediones
ere widely presumed, although not proven, to reduce the
isk for IHD. Subsequently, a number of additional reports
sing alternative meta-analytic techniques (2,3), new meta-
nalyses (4–10), recently published results of new clinical
rials (11–15), and observational studies of both rosiglitazone
nd pioglitazone (16–24) have provided variable evidence
egarding an adverse cardiovascular effect of these agents. On
ovember 14, 2007, after a specially convened FDA Advi-
ory Panel meeting on July 30, 2007, the FDA decided not to
ithdraw rosiglitazone from the market. They issued new
rescribing information that included a new boxed warning
egarding the potential risk for myocardial ischemia, partic-
larly in patients with heart disease taking nitrates, and in
atients for whom rosiglitazone was added to established
nsulin therapy (25).
The American Heart Association and the American College of Cardio
nterest that may arise as a result of an outside relationship or a personal,
ll members of the writing group are required to complete and submit a D
s real or potential conflicts of interest.
This document was approved by the American Heart Association Scie
merican College of Cardiology Foundation Board of Trustees on Dece
The American College of Cardiology Foundation requests that this do
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ermission of the American College of Cardiology Foundation. Please contactDiabetes mellitus is increasing in prevalence in the United
tates and worldwide. An estimated 23.6 million people in
he United States, 7.8% of the population, had diabetes in
007, with more than 90% of cases being type 2 diabetes
ellitus. Diabetes increases the risk of CVD events by 2- to
-fold, and CVD accounts for nearly two thirds of deaths
mong diabetic patients (26). Among people who experience
VD events, diabetes is highly prevalent: 45% of those
ospitalized for acute MI have known or previously undiag-
osed diabetes (27). Diabetes is also an independent predictor
f secondary adverse events, such as reinfarction, heart
ailure, and death (28,29). Similar trends have been observed
n the global incidence of diabetes and its consequences.
mproving care for diabetic patients has therefore become a
lobal health priority (30,31).
The pathophysiology of type 2 diabetes mellitus involves
oth insulin resistance and progressive loss of the insulin-
ecretory capacity of pancreatic beta cells. Prior to the late
990s, pharmacological therapy for type 2 diabetes mellitus
as directed at stimulating or replacing endogenous insulin
ecretion. Insulin resistance precedes the clinical manifesta-
ion of diabetes and has been shown to be associated with
ther cardiovascular risk factors and with increased cardio-
ascular risk (32). The thiazolidinedione class of drugs,
igands of the peroxisome-proliferator–activated receptor-,
hich is intricately involved in insulin signaling, were the
rst drugs developed that directly targeted insulin resistance
33). By improving hepatic and peripheral tissue utilization of
lucose, thiazolidinediones reduce plasma glucose and insu-
in levels and may be associated with improvements in
lasma lipoproteins and certain inflammatory cytokines.
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Thiazolidinedione Drugs and Cardiovascular Risks April 27, 2010:1885–94Two thiazolidinediones are currently available in the
nited States, rosiglitazone (Avandia) and pioglitazone (Ac-
s). A third thiazolidinedione, troglitazone (Rezulin), was
ithdrawn from the market in 2000 because of drug-induced
er injury, including rare cases of hepatic failure and death.
osiglitazone and IHD Risk
o date, there has been only 1 randomized clinical trial
ospectively designed to assess the effect of rosiglitazone on
rdiovascular outcomes, the Rosiglitazone Evaluated for
ardiac Outcomes and Regulation of Glycaemia in Diabetes
ECORD) trial (12,13). The majority of evidence regarding
e cardiovascular effects of rosiglitazone is derived from
eta-analyses of randomized clinical trials that evaluated the
fects of rosiglitazone on glycemic control (1–10). Supple-
entary evidence is also available from observational studies
6–24) and analyses of nonrandomized use of rosiglitazone
clinical trials that focused on glycemic targets rather than
ecified pharmacological interventions (11,14,15).
Table 1 summarizes the characteristics and results of these
udies (see also Figure 1). There are important differences in
ial design, eligibility, follow-up, sample size, analytical
ethods, and outcomes among the studies.
In the RECORD trial, 4447 patients with type 2 diabetes
ellitus that was controlled inadequately with metformin or
lfonylurea were randomized to receive either open-label
d-on rosiglitazone or add-on metformin or sulfonylurea
2,13). The primary objective was to determine whether
siglitazone (plus metformin or sulfonylurea) was noninfe-
or to metformin plus sulfonylurea in reducing the combined
d point of hospitalization or cardiovascular death. An
terim analysis after 3.7 years of follow-up yielded incon-
usive results (12). Recently published results of the com-
eted trial showed that after 5.5 years of follow-up, there
ere 321 events in the rosiglitazone group and 323 in the
ntrol group, which yielded an intention-to-treat hazard ratio
R) of 0.99 (95% confidence interval [CI] 0.85 to 1.16) for
e primary end point, which met the prespecified criterion
r noninferiority (HR less than 1.20) (13). The HR was 1.14
5% CI 0.80 to 1.63) for MI and 0.84 (95% CI 0.59 to 1.18)
r cardiovascular death. Consistent with previous trials,
siglitazone caused an increase in heart failure (HR of 2.10,
% CI 1.35 to 3.27) and fractures (HR of 1.57, 95% CI 1.12
2.19) (13). In a prespecified subgroup analysis, the HR for
e primary end point was 1.26 (95% CI 0.95 to 1.68) among
tients with previous IHD (interaction p0.06, unadjusted
r multiple comparisons). Unfortunately, the RECORD
udy was limited by a lower-than-anticipated event rate,
hich resulted in low power for analysis of the primary end
int, the suboptimal study medication adherence and/or high
ossover rate, and imbalance in disease-modifying therapies
ch as statins and thiazides that favored the rosiglitazone-
eated group (both presumably attributable to the open-label
udy design). As such, the results of RECORD are incon-
usive with respect to the effects of the drug on cardiovas-
lar risk. The data are compatible with as much as a 15%
provement or as much as a 16% worsening in overall
rdiovascular risk and as much as a 20% improvement or as couch as a 63% worsening in risk of MI with rosiglitazone
mpared with metformin plus sulfonylurea.
In the absence of data from adequately powered random-
ed trials, meta-analyses of smaller trials provide the next
st approach to evaluate a relationship between rosiglitazone
d cardiovascular events. In the first large meta-analysis of
inical trials of the effects of rosiglitazone on glycemic
ntrol, Nissen and Wolski (1) examined data from 42 trials
at included 27 847 patients. Their analysis indicated that
eatment with rosiglitazone was associated with an increase
the odds of MI (odds ratio 1.43, 95% CI 1.03 to 1.98,
0.03) and a nonsignificant increase in the odds of cardio-
scular death (odds ratio 1.64, 95% CI 0.98 to 2.74, p0.06)
mpared with a control group (active comparator or pla-
bo) (1). However, this report excluded 4 trials from the MI
alysis and 19 trials from the cardiovascular death analysis
which no events occurred in either trial arm (2,3). Diamond
al. (2) reanalyzed the same clinical trials in the report by
issen and Wolski (1) using methods that allowed the
clusion of zero-event trials that were excluded in the earlier
alysis. Although the resultant odds ratios remained elevated
hich suggests a “signal” for increased risk), the CIs were
ide and overlapped unity, which indicates greater uncer-
inty than was reported originally (2). A different meta-
alysis by Psaty and Furberg (6), in which the unplanned
terim results of RECORD were combined with the meta-
alysis by Nissen and Wolski (1) using the variance-
eighted fixed-effects model, suggested that rosiglitazone
as associated with increased odds for MI (odds ratio 1.33,
% CI 1.02 to 1.72).
The integrated clinical trial analyses conducted by the
aker of rosiglitazone, GlaxoSmithKline (4), and the meta-
alysis conducted by the FDA (5) were based on 42
ndomized trials (only 28 of which overlapped with the
eta-analysis by Nissen and Wolski (1)). The number of
tients included in the GlaxoSmithKline and FDA analyses
as smaller because of the inclusion of only diabetic patients
d double-blind trials; however, patient-level data were
ailable, which allowed more detailed analyses. Both the
laxoSmithKline and FDA meta-analyses, which used
ightly different modeling techniques, concluded that rosigli-
zone was associated with an increase in any IHD event,
cluding unadjudicated chest pain, but no statistically sig-
ficant increase in the composite of cardiovascular death,
I, or stroke. The subgroup analyses in the FDA review
entified a potentially higher risk of adverse events with
siglitazone in patients who were older, had preexistent heart
ilure, or took nitrates, angiotensin-converting enzyme in-
bitors, or insulin (which presumably reflected high-risk
tients with CVD) (5).
Additional meta-analyses have reported inconsistent re-
lts. A Cochrane review did not reveal a statistically signif-
ant increase in the risk of MI (7). In contrast, the meta-
alysis by Singh et al. (8) reported a 42% increase in MI;
wever, there was no significant increase in cardiovascular
ortality (0.90, 95% CI 0.63 to 1.26) or all-cause mortality
.90, 95% CI 0.71 to 1.15). In the meta-analysis by Lago et
. (9), despite a nearly 2-fold increase in the risk of
ngestive heart failure (CHF), rosiglitazone was not associ-
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April 27, 2010:1885–94 Thiazolidinedione Drugs and Cardiovascular Risksed with an increase in risk of cardiovascular death (risk ratio
91, 95% CI 0.63 to 1.32). Shuster et al. (10) observed a
gnificant increase in the risk of cardiovascular death (risk
tio 2.37, 95% CI 1.38 to 4.07), but there was uncertainty
ith regard to the risk of MI (risk ratio 1.51, 95% CI 0.91 to
48). These discordant results may be related to inconsisten-
es in trial design and number, analytical methodology, and
d-point criteria.
Five large observational studies also have examined the
D risk associated with rosiglitazone, 1 commissioned by
laxoSmithKline that used the Ingenix Database and was
own as the Balanced Cohort Study (16) and others con-
cted independently by Tricare for the Department of
efense (17), by WellPoint (18), by the Institute for Clinical
valuative Sciences (Ontario, Canada) (19), and by the
stitute of Health and Welfare Policy/Center for Health and
elfare Policy Research (Taipei, Taiwan) (20). Studies
ried in their design and ability to overcome residual
nfounding and biases. In 3 of the 5 studies, rosiglitazone
as not associated with an increased IHD risk compared with
her antidiabetic agents (16–18). However, the Ontario
udy suggested an increase in the risk of CHF, death, or MI
elderly patients with type 2 diabetes mellitus (19). Simi-
rly, the Taiwanese study reported a higher risk of any
rdiovascular event and MI for patients prescribed rosigli-
zone monotherapy than for patients prescribed metformin
sulfonylurea alone (20). Caution must be observed in
awing definitive conclusions from observational studies
cause of the possibility of bias and confounding, which
ay lead to erroneous conclusions.
Finally, limited data are available from 3 clinical trials of
tensive versus standard glycemic control in patients with
abetes. The intensive blood sugar–lowering treatment arm
the Action to Control Cardiovascular Risk in Diabetes
CCORD) trial (11), a study of more than 10 251 patients
ith diabetes and high cardiovascular risk, reported a 20%
crease in the annual risk of death (from 1.1% to 1.4%) in the
tensive-treatment compared with the standard-treatment
oup; however, preliminary post hoc exploratory analyses do
t suggest a link between differences in the use of drugs
ncluding rosiglitazone) and the increased deaths in the
tensive-treatment group (11). Similarly, the results from the
A Diabetes Trial of 1791 patients randomized to standard or
tensive glucose control do not suggest increased cardiovas-
lar risk with the use of rosiglitazone (HR 0.88, 95% CI 0.74
1.05, p0.14) (14). However, the extensive and nonran-
mized use of rosiglitazone in both arms of the ACCORD
udy (92% in the intensive-treatment group versus 58% in
e standard-treatment group) and the VA Diabetes Trial
2% in the intensive-treatment group versus 62% in the
andard-treatment group) reduces the likelihood of detecting
safety signal associated with rosiglitazone. The results of
e Bypass Angioplasty Revascularization Investigation in
ype 2 Diabetes (BARI 2D) trial, a study of 2368 patients
ith stable coronary artery disease funded by the National
stitutes of Health, suggest that insulin-sensitization agents
etformin or thiazolidinedione; 89% of the thiazolidinedi-
e users received rosiglitazone) are not harmful comparedith insulin-provision treatment (insulin or sulfonylurea) and reay in fact provide a benefit, especially in patients undergo-
g surgical coronary revascularization (15). At 5 years,
ither the rate of survival (88.2% versus 87.9%, difference
3%, 95% CI 2.2% to 2.9%, p0.89) nor the rate of
eedom from major cardiovascular events (77.7% versus
.4%, difference 2.4%, 95% CI 1.2 to 6.0, p0.13)
ffered significantly between the insulin-sensitization group
d the insulin-provision group. Patients randomized to both
ronary artery bypass graft surgery and insulin-sensitization
erapy had a significantly lower rate of major cardiovascular
ents than any of the other treatment-combination groups
5). Because of the design of the BARI 2D trial, it is not
ssible to determine whether the findings with the insulin-
nsitization agents apply to metformin monotherapy, thiazo-
inedione monotherapy, or their combination.
In summary, an association between rosiglitazone and IHD
tcomes has not yet been firmly established. Additional
ospective clinical trials designed for the specific purpose of
tablishing the cardiovascular benefit or risk of rosiglitazone
ould be the best way to resolve the uncertainties regarding
e safety of rosiglitazone. However, sufficient evidence has
erged to raise concerns about a potential adverse effect.
hese uncertainties were reflected in the vote of the FDA
dvisory Panel, who on July 30, 2007, voted 20 to 3 in favor
an increased risk for ischemic cardiac events with rosigli-
zone but voted 22 to 1 against removing rosiglitazone from
e market (34). On October 18, 2007, the European Medi-
nes Agency issued a statement that concluded that “the
nefits of both rosiglitazone and pioglitazone in the treat-
ent of type 2 diabetes continue to outweigh their risks.” (35)
he FDA’s decision on November 14, 2007, to allow rosigli-
zone to remain on the market with an additional boxed
arning about the risk of IHD events further reflects these
certainties (25). The FDA stated that additional studies
ave not confirmed or excluded this risk. In their entirety,
e available data on the risk of myocardial ischemia are
conclusive.” Given this clinical equipoise, we call on
ademic researchers, industry, and government agencies to
llaborate on definitive randomized trials to answer these
portant clinical questions.
ioglitazone and IHD Risk
able 2 summarizes the characteristics and results of studies
garding IHD risk of pioglitazone (see also the Figure). A
rge clinical trial designed to assess the effect of pioglitazone
ischemic cardiovascular outcomes, the PROactive trial
ROspective pioglitAzone Clinical Trial In macroVascular
vents), showed no statistically significant effect of pioglita-
ne on the primary composite outcome (HR 0.90, 95% CI
80 to 1.02) (36). However, pioglitazone treatment signifi-
ntly reduced a secondary composite outcome of all-cause
ortality, nonfatal MI, and stroke (HR 0.84, 95% CI 0.72 to
98). Nevertheless, this finding awaits confirmation in an
ditional prospective clinical trial.
A meta-analysis of 19 trials (in which nearly 80% of
oled events were contributed by the PROactive trial)
ported a significant reduction in the composite end point of
Ta
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Thiazolidinedione Drugs and Cardiovascular Risks April 27, 2010:1885–94ble 1. Studies of Rosiglitazone and IHD Risk
dy
Design
(Treatment) Follow-Up
No. of Trials
(Sample Size)
Analytical
Method Outcomes of Interest Results Interpretation
G randomized trial
RECORD (13) RCT of diabetics,
open-label
(RSGMET/SU vs
METSU)
5.5 y 1 (4447) Noninferiority
analysis (HR)
CV death/CV
hospitalization
MI
CV death
0.99 (0.85–
1.16)
1.14 (0.80–
1.63)
0.84 (0.59–
1.18)
Limitations in trial
design and
conduct preclude
reliable
interpretation of
the results
G meta-analyses
Nissen and
Wolski (1)
RCTs of diabetics,
prediabetics,
nondiabetics;
double-blind and
open-label (RSG
vs placebo/
active Rx)
24 wk 42 (27 847) Peto
fixed-effects
model (OR)
MI
CV death
1.43 (1.03–
1.98)
1.64 (0.98–
2.74)
Significant
increase in the
risk of MI and
borderline
increase in risk of
CV death
Diamond et al. (2) As Nissen and
Wolski1
24 wk 42 (27 847) Mantel-Haenszel
fixed-effects
model with
continuity
correction (OR)
MI
CV death
1.26 (0.93–
1.69)
1.17 (0.77–
1.77)
Uncertainty in the
risk of MI and CV
death
Psaty and
Furberg (6)
As Nissen and
Wolski1 plus
RECORD
(open-label) (RSG
vs placebo/
active Rx)
24 wk 43 (32 294) Variance-
weighted fixed-
effects model
(OR)
MI 1.33 (1.02–1.72) Significant
increase in risk of
MI
ICT (GSK) (4) RCTs of diabetics;
double-blind only
(RSG vs placebo/
active Rx)
Average 6
mo
42 (14 237) Multivariable
Cox proportional
hazards model
(HR)
IHD
CV death/MI/stroke
1.31 (1.01–
1.70)
1.16 (0.80–
1.70)
Increased risk of
IHD, uncertain CV
death/MI/stroke
risk
FDA (5) As ICT4 Average 6
mo
42 (14 237) (1) Exact test
(OR); (2)
Mantel-Haenszel
fixed-effects
model with
continuity
correction (OR)
IHD
CV death/MI/stroke
1.39 (1.1–1.8)
1.15 (0.8–1.6)
Increased risk of
IHD, uncertain CV
death/MI/stroke
risk
Cochrane review (7) RCTs of diabetics;
double-blind and
open-label (RSG
vs placebo/active
Rx)
24 wk 18 (3888) Fixed-effects
model (OR)
MI 0.91 (0.75–1.71) No significant
increase in risk of
MI
Singh et al. (8) RCTs of diabetics,
prediabetics (RSG
vs placebo/active
Rx)
1 y 4 (14 291) Fixed-effects
model (RR)
MI
CV death
1.42 (1.06–
1.91)
0.90 (0.63–
1.26)
Significantly
increased risk of
MI, no significant
increase in risk of
CV death
Lago et al. (9) RCTs of diabetics,
prediabetics;
double-blind (RSG
vs placebo/active
Rx)
Average
29.7 mo
5 (14 491) Random-effects
model (RR)
CV death 0.91 (0.63–1.32) No significant
increase in risk of
CV death
Shuster et al. (10) As Nissen and
Wolski1 plus 6
trials excluded by
Nissen and Wolski
24 wk 48 (NA) Random-effects
model (RR)
MI
CV death
1.51 (0.91–
2.48)
2.37 (1.38–4.07)
Uncertainty in risk
of MI, significant
increase in risk of
CV death
G observational
ta
Ingenix study (16) Retrospective
cohort study of
diabetics (RSG vs
non-RSG active
Rx)
1.2 y 1 (33 363) Propensity-
matched Cox
proportional
hazard
model (HR)
MI/CR
MI
0.93 (0.80–
1.10)
0.92 (0.73–
1.16)
No significant
increase in risk of
MI and/or
revascularization
(Continued)
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April 27, 2010:1885–94 Thiazolidinedione Drugs and Cardiovascular Risksl-cause death, MI, or stroke with pioglitazone compared
ith control (HR 0.82, 95% CI 0.72 to 0.94) (37). Observa-
nal studies suggest no increased IHD risk with pioglitazone
mpared with other oral hypoglycemic agents (18–20).
In summary, the majority of published studies do not
ggest an increased hazard for IHD events in pioglitazone-
eated patients. Accordingly, there is no boxed warning on
e risk of IHD for pioglitazone.
udy
CORD
End Point
CV death/CV hospit
MI
Type (No. of Trials)
RCT (1)
ssen & Wolski
iamond et al.
CV death
MI
CV death
MI
Meta-analysis (42)
Meta-analysis (42)
saty & Furberg
T
A
CV death
MI
IHD
CV death/MI/stroke
Meta-analysis (43)
Meta-analysis (42)
M t l i  (42)
chrane
ngh et al.
MI
MI
CV death
IHD
CV death/MI/stroke
Meta-analysis (18)
Meta-analysis (4)
e a-ana ys s
go et al.
uster et al.
CV death
 
CV death
MI
Meta-analysis (5)
Meta-analysis (48)
Oactive RCT (1)
ncoff et al.
Death/MI/stroke
Meta-analysis (19)
Death/MI/stroke/AC
intervention/amputa
Death/MI/stroke
alization
S/vascular
tion 
0.1
ble 1. Continued
dy
Design
(Treatment) Follow-Up
No. of Trials
(Sample Size)
WellPoint study (18) Observational
study of diabetics
(RSG vs non-RSG
active Rx)
NA 1 (142 821) Cox
h
Ontario study (19) Retrospective
case-control study
of elderly
diabetics (RSG
vs non-RSG
active Rx)
3.8 y 1 (159 026)
reg
Taiwan study (20) Retrospective
cohort study of
diabetics (RSG*
vs non-RSG
active Rx)
NA 1 (473 000) Mu
p
m
ACM indicates all-cause mortality; CR, coronary revascularization; CV, cardiovascular; G
ailable; OR, odds ratio; RCT, randomized, controlled trial; RR, risk ratio; RSG, rosiglitazon
*Only 2093 patients (0.44) received RSG alone; any CV event includes the composite ouRR (log scale)ioglitazone Versus Rosiglitazone
nd IHD Risk
here are currently no prospective randomized, controlled
ials that have examined the risk of IHD events associated
ith pioglitazone compared with rosiglitazone. Observa-
onal studies have reached different conclusions regarding
e relative safety of pioglitazone compared with rosigli-
10
Figure 1. Thiazolidinediones and IHD risk
based on randomized controlled trials
(closed and open squares) and their meta-
analyses (closed and open diamonds). Data
for rosiglitazone are shown as closed
squares and diamonds, whereas data for
pioglitazone are shown as open squares and
diamonds. There is overlap among the indi-
vidual studies included in the different meta-
analyses. RCT indicates randomized, con-
trolled trial; CV, cardiovascular; ICT,
integrated clinical trial; and ACS, acute coro-
nary syndrome.
l
Outcomes of Interest Results Interpretation
onal
)
MI 1.03 (0.89–1.19) No significant
increase in risk of
MI
RR)
MI
Death
1.76 (1.27–
2.44)
1.47 (1.12–
1.93)
Increased risk of
MI and death
Cox
al
)
Any CV event (vs SU)
Ay CV event (vs MET)
MI (vs SU)
MI (vs MET)
1.54 (1.29–
1.85)
1.89 (1.57–
2.28)
1.49 (0.99–
2.24)
2.09 (1.36–
3.24)
Increased risk of
any CV event and
MI, especially
compared with
MET
oSmithKline; HR, hazard ratio; ICT, integrated clinical trials; MET, metformin; NA, not
eatment; and SU, sulfonylurea.
any of the 5 events of MI, CHF, stroke, transient ischemic attack, or angina pectoris.1Analytica
Method
proporti
azard (HR
Logistic
ression (
ltivariate
roportion
hazard
odel (HR
SK, Glax
e; Rx, tr
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Thiazolidinedione Drugs and Cardiovascular Risks April 27, 2010:1885–94zone (Table 2). One large study that used Taiwan’s
ational Health Insurance database suggested a nonsignif-
ant association toward a more favorable overall cardio-
ble 2. Studies of Pioglitazone and IHD Risk
dy Design (Treatment) Follow-Up
No. of Trials
(Sample Size)
O randomized trial
PROactive Study (36) RCT of
diabetics (PIO vs
placebo)
34.5 mo 1 (5238)
O meta-analysis
Lincoff et al. (37) RCT of
diabetics (PIO vs
non-PIO active Rx)
4 mo to 3.5 y 19 (16 390)
O observational data
WellPoint study (18) Observational study
of diabetics (PIO vs
non-PIO active Rx)
NA 1 (144 531)
Ontario study (19) Retrospective case-
control study of
elderly
diabetics (PIO vs
non-PIO active Rx)
3.8 y 1 (159 026)
Taiwan study (20) Retrospective
cohort study of
diabetics (PIO* vs
non-PIO active Rx)
NA 1 (473 000)
O vs RSG
servational data
Taiwan study (20) Retrospective
cohort study of
diabetics (add-on
PIO vs add-on RSG
with SU and MET-
based Rx)
NA 1 (473 000)
Ingenix study (21) Retrospective
cohort study of
diabetics (PIO vs
RSG)
1.3 y PIO
1.2 y RSG
1 (29 911)
Winkelmayer
et al. (22)
Retrospective
cohort study of
elderly
diabetics (PIO vs
RSG)
1.0 y PIO
1.0 y RSG
1 (28 361)
Juurlink et al. (23) Retrospective
cohort study of
elderly
diabetics (PIO vs
RSG)
72 mo 1 (39 736)
Dormuth et al. (24) Nested case-
control study of
diabetics taking
MET (RSG vs PIO or
SU)
47 mo 1 (158 578)
ACS indicates acute coronary syndromes; CR, coronary revascularization; CV, cardiovascu
, pioglitazone; RCT, randomized, controlled trial; RR, risk ratio; RSG, rosiglitazone; Rx, t
*Only 495 patients (0.10) received PIO alone; any CV event includes the composite outcscular effect in those individuals prescribed add-on moglitazone compared with add-on rosiglitazone (20).
owever, an increased risk of MI was observed with the
dition of pioglitazone compared with rosiglitazone to
lytical Method
Outcomes of
Interest Results Interpretation
proportional
azard (HR)
Death/MI/
stroke/ACS/
vascular
intervention/
amputation
0.90 (0.80–1.02) Nonsignificant
reduction in
composite ischemic
events
xed-effects
odel (HR)
Death/MI/stroke 0.82 (0.72–0.94) Significant reduction
in risk of ischemic
vascular events
proportional
azard (HR)
MI 1.04 (0.91–1.21) No significant
increase in risk of
MI
Logistic
ression (RR)
MI
Death
0.73 (0.40–
1.36)
0.94 (0.61–
1.45)
No increased risk of
MI and death with
PIO
ltivariate Cox
roportional
rd model (HR)
Any CV
event (vs SU)
Any CV
event (vs MET)
MI (vs SU)
MI (vs MET)
1.03 (0.65–
1.65)
1.29 (0.81–
2.07)
0.72 (0.19–
2.77)
1.00 (0.26–
3.89)
No increased risk of
any CV event or MI,
but wide CIs due to
small sample size
ltivariate Cox
roportional
rd model (HR)
MI (SU-based
Rx)
MI (MET-
based
Rx)
MI (SUMET-
based Rx)
0.69 (0.30–
1.55)
6.34 (1.80–
22.31)
1.04 (0.73–
1.47)
Increased risk of MI
with addition of PIO
to MET, but wide
CIs indicate limited
statistical power
ltivariate Cox
roportional
rd model (HR)
MI/CR
MI
0.85 (0.63–
0.96)
0.78 (0.75–
0.98)
22 Lower risk of MI
and/or
revascularization
with PIO
ltivariate Cox
roportional
rd model (IRR)
Death
MI
0.87 (0.79–
0.95)
0.93 (0.80–
1.08)
13 Lower risk of
death, but not MI,
with PIO
ltivariate Cox
roportional
rd model (HR)
Death/MI/
CHF
Death
MI
0.83 (0.76–
0.90)
0.86 (0.75–
0.98)
0.95 (0.81–
1.11)
Significant reduction
in composite events
and death, but not
MI, with PIO
itional logistic
regression
odel (OR)
MI (vs PIO)
MI (vs SU)
1.00 (0.67–
1.49)
0.90 (0.69–
1.17)
No increased risk of
MI with addition of
RSG vs PIO or SU in
prior MET users
hazard ratio; IRR, incident rate ratio; MET, metformin; NA, not available; OR, odds ratio;
; and SU, sulfonylurea.
ny of the 5 events of MI, CHF, stroke, transient ischemic attack, or angina pectoris.Ana
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April 27, 2010:1885–94 Thiazolidinedione Drugs and Cardiovascular Risksmited statistical power for this observation (20). Another
udy suggested a 22% lower risk of MI with pioglitazone
mpared with rosiglitazone (21). Two additional studies
at used insurance claims databases for elderly patients
ith diabetes in New Jersey and Pennsylvania (22) and in
e province of Ontario (23) found that pioglitazone was
sociated with a reduced risk of overall mortality and
HF but not MI compared with rosiglitazone. Finally, in a
sted case-control study in British Columbia, in a cohort
prior metformin users, the addition of rosiglitazone was
t associated with an increased risk of MI compared with
e addition of a sulfonylurea or the addition of pioglita-
ne (24).
Taken together, these observations add further uncertainty
ith regard to the cardiovascular risk associated with thiazo-
inediones. Substantial differences between the pioglitazone
d rosiglitazone meta-analyses exist, e.g., placebo-
ntrolled versus active-controlled trials, patient demograph-
s, and treatment duration. Each of these factors potentially
n have a material impact on outcomes. This type of indirect
mparison is potentially misleading, may result in conflict-
g results depending on the end points compared, and
nerally should be avoided. Healthcare databases used in
servational studies are limited by bias and confounding,
d therefore, they are not particularly well suited for
awing definitive conclusions to impact policy or clinical
actice recommendations. There are some differences among
e thiazolidinediones with respect to changes in lipid profile;
oglitazone has more favorable effects on serum lipids than
es rosiglitazone (38). Although these metabolic differences
e expected to result in lower rates of IHD events with
oglitazone, only direct head-to-head comparisons of out-
mes data in prospective randomized trials can provide
nvincing conclusions about the comparability of these 2
ents.
hiazolidinediones and Heart Failure Risk
he effects of thiazolidinediones in exacerbating CHF have
en detailed in a previously published American Heart
ssociation/American Diabetes Association scientific state-
ent (39). A meta-analysis by Lago et al. (9) demonstrated a
7-fold increase in risk of CHF with thiazolidinediones, with
slightly greater increase in risk with rosiglitazone (2.2-fold)
an with pioglitazone (1.3-fold), although the between-
eatment differences were not statistically significant. De-
ite the increase in risk of CHF, no increase in risk of
rdiovascular death was observed with either thiazolidinedi-
e, which leads one to question whether the volume reten-
n/weight gain associated with thiazolidinediones is prog-
stically benign or harmful. Lincoff et al. (37) also reported
increase in the risk of CHF (1.4-fold) but not ischemic
rdiovascular outcomes with pioglitazone. This, together
ith the observation that rosiglitazone did not adversely
fect left ventricular systolic or diastolic function in patients
ith type 2 diabetes mellitus and New York Heart Associa-
n functional class I or II CHF despite edema and weight
in (40), raises question about the link between thiazo-
inediones and CHF exacerbation. Furthermore, these find- thgs reinforce the message for establishing the clinical diag-
sis of heart failure on the basis of associated symptoms
uch as orthopnea, paroxysmal nocturnal dyspnea, unex-
ained cough or fatigue, or pedal edema) and signs (such as
gular venous distention, an S3 gallop, and pulmonary rales)
patients with volume retention or weight gain while taking
iazolidinediones (39). Nonetheless, as summarized in the
oduct label for both drugs, caution is urged for the use of
siglitazone or pioglitazone in all patients with signs and
mptoms suggestive of CHF. Initiation of either agent is
ntraindicated in patients with class III or IV CHF (41).
ecommendations to Reduce
ascular Disease in Patients With
ype 2 Diabetes Mellitus
iabetes is considered a coronary heart disease equivalent in
ults older than 40 years. There is substantial clinical trial
d other evidence that the standard secondary prevention
rategies also affect the risk for coronary heart disease events
patients with type 2 diabetes mellitus. Thus, the corner-
one for prevention of IHD events in patients with type 2
abetes mellitus includes tobacco avoidance, maintenance of
timal body weight, diet, physical activity, control of blood
essure and lipids (with statins as first-line therapy), and use
aspirin. The American Heart Association and the American
ollege of Cardiology have published guidelines for CVD
evention that extend to patients with diabetes (42). The
merican Diabetes Association and European Association
r the Study of Diabetes have issued a consensus statement
ith a related algorithm on the medical management of
perglycemia (43). That statement indicates that a hemoglo-
n A1c level greater than or equal to 7% should serve as a call
action to initiate or change therapy, with the goal of
hieving a hemoglobin A1c level less than 7%. Recent
atements have been published in an attempt to harmonize
e recommendations of the American Heart Association,
merican College of Cardiology, and American Diabetes
ssociation (44).
In addition to conventional secondary prevention strate-
es, the current guidelines for patients with type 2 diabetes
ellitus recommend that if lifestyle modifications including
gh-quality diet, physical activity, and weight reduction are
sufficient to achieve the glycemic targets, antidiabetic
ents should be considered. There are 10 classes of antidi-
etic agents currently available (43): Biguanides (met-
rmin), glinides (repaglinide, nateglinide), sulfonylureas,
pha-glucosidase inhibitors, thiazolidinediones, incretin mi-
etics (glucagon-like peptide-1 mimetics), dipeptidyl
ptidase-IV inhibitors, amylin analogs (pramlintide), bile
id sequestrants (colesevelam), and insulin. However, it is
portant to recognize that the recommendation for glycemic
ntrol is based principally on evidence for reduced micro-
scular risk in patients with type 2 diabetes mellitus, which
available for some but not all glucose-lowering pharmaco-
gical therapies. Despite the favorable effects these therapies
ve on cardiometabolic risk profile (glucose control, insulin
sistance, and dyslipidemia), there is a paucity of evidence
at any glucose-lowering agent reduces macrovascular risk,
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Thiazolidinedione Drugs and Cardiovascular Risks April 27, 2010:1885–94d as reviewed above, there are questions about whether
siglitazone or even intensive glycemic control may have
verse effects on risk for IHD. Of the available agents,
etformin in obese patients with type 2 diabetes mellitus has
ovided the strongest evidence of CVD benefit (45), includ-
g long-term benefits that persisted up to 10 years after
mpletion of the United Kingdom Prospective Diabetes
udy (UKPDS; vide infra) (46).
Where should glucose-lowering agents, including thiazo-
inediones, be placed in the list of therapeutic options to
event vascular disease in patients with type 2 diabetes
ellitus? A prospective randomized study of obese patients
rolled in the UKPDS demonstrated significant reductions in
abetes-related deaths (42% risk reduction, p0.017), any
abetes-related end point (32% risk reduction, p0.0023),
d MI (39% risk reduction, p0.01) in patients treated with
etformin (45). In a smaller subgroup in the UKPDS study in
hich metformin was added early to sulfonylurea-treated
tients, there was an increase in diabetes-related deaths (45).
evertheless, on the basis of the UKPDS data, the absence of
idence of any adverse cardiovascular effects, the existence
few other adverse side effects, and its low cost, metformin
generally recommended as first-line therapy to be initiated
ong with lifestyle modification, especially in obese diabetic
tients. There is no consensus concerning which of the
maining classes of agents should be used next to achieve
e recommended glycemic targets to reduce microvascular
mplications, nor is it well established what effect these
ents may have on risk for macrovascular disease.
On the basis of all available evidence, thiazolidinediones
ould not be used with an expectation of benefit with respect
IHD events. Thiazolidinediones should be used with the
derstanding that they might increase the risk of heart
ilure. Of the 2 currently available thiazolidinediones, meta-
alyses have raised important concerns about a potential
verse effect of rosiglitazone on IHD, a concern that has not
en raised by the available data for pioglitazone. However,
ere remains an inadequate foundation of randomized clin-
al trials to properly judge the safety or efficacy of either
ent with respect to IHD events. Thus, patients who have
ccessfully achieved recommended glycemic control with a
iazolidinedione might consider remaining on their medica-
n; however, if either the treating physician or the patient is
comfortable continuing with a thiazolidinedione, another
edication could be substituted, with the recognition that the
nd of knowledge about the effect of other glucose-lowering
ents on IHD risk is similarly sparse.
ecommendations to the Clinical
ommunity, Pharmaceutical Industry,
nd Regulatory Agencies Concerning
reatments for Type 2 Diabetes Mellitus
he controversy over the unexpected findings from the meta-
alyses of rosiglitazone glycemic control trials coupled with the
milarly unexpected findings from the ACCORD trial has
masked major deficiencies in our understanding of the role of
ycemia in the pathogenesis and prevention of IHD in type 2
abetes mellitus. Given the large and continually increasing thmber of people with type 2 diabetes mellitus and the magni-
de of the attendant burden of IHD in these patients, it is
cumbent on the medical community to identify optimal strat-
ies to prevent both the microvascular and macrovascular
mplications of the disease. Unfortunately, as the rosiglitazone
se illustrates, clinical trials focused purely on glycemic control
the primary outcome do not provide the quality of evidence
quired to make informed decisions regarding the clinical
ficacy and safety of glucose-lowering regimens with respect to
th microvascular and macrovascular disease. The clinical
mmunity must insist on having adequate data to make deci-
ons about optimal treatment for their patients with type 2
abetes mellitus, including properly designed randomized trials
ith subclinical and clinical cardiovascular outcomes as the
imary or important secondary outcomes. The pharmaceutical
dustry should immediately initiate appropriately designed
inical trials of currently approved glucose-lowering agents to
termine their effect on clinical cardiovascular events. Finally,
e FDA and other regulatory agencies should require that such
ials be included as part of the initial or ongoing evaluation of
w glucose-lowering agents and explore novel strategies such
phased approval and other measures to permit clinical efficacy
d safety data to be generated without causing undue delays in
significant barriers to the development of urgently needed
erapies to prevent all forms of vascular disease in patients with
pe 2 diabetes mellitus.
ummary
inimization of the risk of microvascular and macrovascular
sease is a critical clinical goal in the management of
tients with diabetes. Control of hyperglycemia is recom-
ended to reduce microvascular complications; achievement
a hemoglobin A1c less than 7% without causing hypogly-
mia may be particularly important, if accomplished early in
e disease and maintained successfully. Attainment of this
ycemic goal when lifestyle modification is not enough will
quire a choice of 1 or more glucose-lowering agents.
Conventional risk-reduction measures, such as lifestyle
odification, the use of aspirin (especially in patients with
eexisting CVD), and appropriate blood pressure– and
id-lowering drugs, are of proven benefit in reducing
acrovascular disease and saving lives; however, the evi-
nce concerning the effects of specific glucose-lowering
ents on macrovascular disease is limited and inconclusive.
here is evidence that suggests a macrovascular benefit with
etformin, especially for obese diabetic patients, and some
conclusive evidence of potential harm from rosiglitazone
t not pioglitazone. For most of the other glucose-lowering
ents, there are few or no data to support either harm or
nefit with regard to macrovascular disease.
More data are urgently needed to clarify the effects of all
isting and future glucose-lowering agents, including thia-
lidinediones, on IHD events. In the meantime, patients and
inicians will need to weigh the accepted benefits of im-
oved glycemic control on risk for microvascular disease
om glucose-lowering agents against the worrisome, incon-
usive, or completely absent information about the effects of
ese agents on macrovascular disease.
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he following are keys to patient management:
Identification and treatment of correctable risk factors
– Smoking cessation
– High-quality diet
– Weight control
– Exercise
Use of established secondary prevention strategies
– Aspirin (or clopidogrel in patients intolerant of aspirin)
– Lipid lowering, with statins as the first-line therapy
– Blood pressure lowering
Early and consistent attention to controlling hyperglyce-
mia while avoiding hypoglycemia
– Metformin is generally first-line therapy, particularly in
obese patients
– Thiazolidinediones should not be used with an expecta-
tion of benefit with respect to IHD events
– Insufficient data exist to support the choice of piogli-
tazone over rosiglitazone
– Thiazolidinediones increase the risk of heart failure
and should not be initiated in patients with class
III/IV CHF
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